歐盟否決罕見疾病療法，Zevra 股價重挫 (ZVRA:NASDAQ)
· seekingalpha.com
Zevra Therapeutics (ZVRA) 在歐盟藥品管理局建議小組拒絕為其罕見疾病藥物 arimoclomol 背書後，股價大幅下跌。欲了解詳情請點擊此處。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...